Institute for Developmental Sciences, University of Southampton and Southampton University Hospitals Trust, Southampton, UK.
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):265-71. doi: 10.1016/j.plefa.2010.02.012. Epub 2010 Mar 2.
Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver damage, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. NAFLD is strongly associated with insulin resistance and is defined by accumulation of liver fat >5% per liver weight in the presence of <10g of daily alcohol consumption. The exact prevalence of NAFLD is uncertain because of the absence of simple noninvasive diagnostic tests to facilitate an estimate of prevalence but in subgroups of people such as those with type 2 diabetes, the prevalence may be as high as 70%. NASH is an important subgroup within the spectrum of NAFLD that progresses over time with worsening fibrosis and cirrhosis, and NASH is associated with increased risk for cardiovascular disease. It is, therefore, important to understand the pathogenesis of NASH specifically, to develop strategies for interventions to treat this condition. The purpose of this review is to discuss the roles of inflammation, fatty acids and fatty acids in nutrition, in the pathogenesis and potential treatment of NAFLD.
非酒精性脂肪性肝病(NAFLD)是指一系列肝脏损伤,从轻度单纯性肝脂肪变性到非酒精性脂肪性肝炎(NASH)、进展性肝纤维化和肝硬化。NAFLD 与胰岛素抵抗密切相关,其定义为在每日酒精摄入量<10g 的情况下,肝脏脂肪堆积>肝脏重量的 5%。由于缺乏简便的非侵入性诊断检测方法来估计患病率,因此确切的 NAFLD 患病率尚不确定,但在某些亚组人群中,如 2 型糖尿病患者,患病率可能高达 70%。NASH 是 NAFLD 谱中的一个重要亚组,随着纤维化和肝硬化的恶化而逐渐进展,并且 NASH 与心血管疾病风险增加相关。因此,了解 NASH 的发病机制对于制定治疗这种疾病的干预策略非常重要。本文的目的是讨论炎症、脂肪酸和营养中的脂肪酸在 NAFLD 的发病机制和潜在治疗中的作用。